Global Overactive Bladder Therapeutics Market 2017-2021

  • ID: 4319179
  • Report
  • Region: Global
  • 96 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • Ferring
  • Hisamitsu Pharmaceutical
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Sanofi
  • MORE

About Overactive Bladder (OAB) Therapeutics

Overactive bladder (OAB) is a syndrome that manifests complex symptoms such as urinary urgency with or without urinary incontinence accompanied by increased frequency and nocturia. The disease is more prevalent in women than in men, and the prevalence rate is directly proportional to age, i.e., the prevalence rate of OAB increases with the increase in age. Global OAB therapeutics market is currently dominated by anticholinergic agents, which exert its pharmacologic effect by inhibiting the neurotransmitter acetylcholine in the central and peripheral nervous system. However, the on-going research in new areas such as gene therapy can lead to change in the treatment landscape, going forward.

The analysts forecast the global Overactive Bladder (OAB) Therapeutics market to grow at a CAGR of 1.56% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global Overactive Bladder (OAB) Therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Overactive Bladder (OAB) Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors

  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Pfizer

Other prominent vendors

  • Ferring
  • GlaxoSmithKline
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • Lanzhou Institute of Biological Products
  • Merck
  • ONO Pharmaceutical
  • Sanofi
  • Tengion
  • Teva Pharmaceutical Industries

Market drivers

  • Growing geriatric population
  • For a full, detailed list, view the full report

Market challenges

  • Rise in economic burden of OAB
  • For a full, detailed list, view the full report

Market trends

  • Advancing biomedical science
  • For a full, detailed list, view the full report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • Ferring
  • Hisamitsu Pharmaceutical
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Sanofi
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
Market outline

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Pipeline analysis

PART 07: Market segmentation based on drug class
Management of OAB
Anticholinergic agents
Beta-3-adrenoreceptor agonists
Others

PART 08: Drug profile of key OAB therapeutics
TOVIAZ
VESIcare
Betanis/Myrbetriq/BETMIGA

PART 09: Geographical segmentation
OAB therapeutics market in Americas
OAB therapeutics market in EMEA
OAB therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
Market drivers
Market challenges

PART 12: Market trends
Advancing biomedical science
Advent of novel drug delivery systems
Gene therapy in OAB

PART 13: Vendor landscape
Competitive scenario

PART 14: Key vendor analysis
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Other prominent vendors

PART 15: Appendix
List of abbreviations

List of Exhibits
Exhibit 01: Prevalence rate of OAB in women aged under 25 years versus women aged over 65 years
Exhibit 02: OAB pathophysiology
Exhibit 03: Global OAB therapeutics market snapshot

Exhibit 04: Global OAB therapeutics market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global OAB therapeutics market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline molecules at various developmental stage
Exhibit 08: Pipeline molecules arranged as per drug class
Exhibit 09: Key clinical trials
Exhibit 10: Purpose of key clinical trials
Exhibit 11: Segmentation of global OAB therapeutics market by drug class 2016
Exhibit 12: Global OAB therapeutics market share by drug class, 2016
Exhibit 13: Global OAB therapeutics market segmentation by drug class 2016
Exhibit 14: Global OAB anticholinergic therapeutics market 2016-2021 ($ millions)
Exhibit 15: Types of ACh receptors
Exhibit 16: Mechanism of action of MRA
Exhibit 17: Global OAB beta-3 adrenoreceptor agonists market 2016-2021 ($ millions)
Exhibit 18: Mechanism of action of mirabegron
Exhibit 19: Global OAB therapeutics market for others 2016-2021 ($ millions)
Exhibit 20: TOVIAZ year-over-year (YoY) revenue 2010-2016 ($ millions)
Exhibit 21: VESIcare revenue in different regions in 2015-2016 ($ millions)
Exhibit 22: Betanis/Myrbetriq/BETMIGA revenue in different regions 2015-2016 ($ millions)
Exhibit 23: Betanis/Myrbetriq/BETMIGA patents
Exhibit 24: History of drug approvals in OAB
Exhibit 25: Segmentation of global OAB therapeutics market by geography 2016 and 2021
Exhibit 26: Global OAB therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 27: Global OAB therapeutics market share by geography 2016-2021 (%)
Exhibit 28: Global OAB therapeutics market scenario in different regions
Exhibit 29: Market scenario in Americas
Exhibit 30: OAB therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 31: Prevalence rate of OAB in US 2007
Exhibit 32: Market scenario in EMEA
Exhibit 33: OAB therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: OAB therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 36: Probability of continuing antimuscarinic treatment in patients depending on their age
Exhibit 37: Geriatric population analysis by geography 2000 and 2030 (estimated) (in millions)
Exhibit 38: Prevalence rate of OAB in different age groups in Finland 2003-2004 (%)
Exhibit 39: OAB-POLL survey in US adults 2010
Exhibit 40: Telephonic interview evaluating the treatment outcomes with antimuscarinic agents in OAB patients
Exhibit 41: Competitive structure analysis of global OAB therapeutics market 2016
Exhibit 42: Allergan: Key highlights
Exhibit 43: Allergan: Strength assessment
Exhibit 44: Allergan: Strategy assessment
Exhibit 45: Allergan: Opportunity assessment
Exhibit 46: Astellas Pharma: Key highlights
Exhibit 47: Astellas Pharma: Strength assessment
Exhibit 48: Astellas Pharma: Strategy assessment
Exhibit 49: Astellas Pharma: Opportunity assessment
Exhibit 50: Hisamitsu Pharmaceutical: Key highlights
Exhibit 51: Hisamitsu Pharmaceutical: Strength assessment
Exhibit 52: Hisamitsu Pharmaceutical: Strategy assessment
Exhibit 53: Hisamitsu Pharmaceutical: Opportunity assessment
Exhibit 54: Pfizer: Key highlights
Exhibit 55: Pfizer: Strength assessment
Exhibit 56: Pfizer: Strategy assessment
Exhibit 57: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • Ferring
  • Hisamitsu Pharmaceutical
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Sanofi
  • MORE
New Report Released: – Global Overactive Bladder (OAB) Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global overactive bladder (OAB) therapeutics market: Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, and Pfizer.

Other Prominent Vendors in the market are: Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is advancing biomedical science. In the past few decades, the advancement in science and introduction of nanotechnologies in the global pharmaceutical market have revolutionized the development of medicines. With a better understanding of the pathogenesis of disease at genetic and molecular levels has led to the discovery of new targets for therapy, thus producing disease-modifying drugs. Modern techniques such as bioinformatics, molecular targeting, nanotechnology, and personalized medicines have facilitated drug development in the area of neurodegenerative disorders.”

According to the report, one of the major drivers for this market is growing geriatric population. OAB is a chronic disorder, characterized by increased frequency of urination and nocturia. Several studies have revealed that the risk of developing OAB increases with age and is most common among the older population. Also, as the disorder is non-life threatening in nature, it has been observed that the probability of complying with the medication treatment for OAB is high among older patients than in adults aged lesser than 55 years.

Further, the report states that one of the major factors hindering the growth of this market is Rise in economic burden of OAB. Urinary incontinence (involuntary loss of urine), stress urinary incontinence (involuntary loss of urine accompanied by increased abdominal pressure), and OAB (increased urgency, frequency, and nocturia) represents a major public healthcare concern. OAB affects one out of seven US adults, and the prevalence of the disease is equal to both men and women. The lack of disease-modifying drugs for the treatment of OAB unnecessarily prolongs the treatment duration, thus increasing treatment cost. Also, the rise in geriatric population in the US too increases the economic burden of disease on individuals and payers.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Allergan
  • Astellas Pharma
  • Ferring
  • GlaxoSmithKline
  • Hisamitsu Pharmaceutical
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • Lanzhou Institute of Biological Products
  • Merck
  • ONO Pharmaceutical
  • Pfizer
  • Sanofi
  • Tengion
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll